登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，9月25日，Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-10-14

  • Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

    Jianhui Nie, Qianqian Li, Jiajing Wu, Chenyan Zhao, Huan Hao, Huan Liu, Li Zhang, Lingling Nie, Haiyang Qin, Meng Wang, Qiong Lu, Xiaoyu Li, Qiyu Sun, Junkai Liu, Changfa Fan, Weijin Huang, Miao Xu & Youchun Wang

    Nature Protocols (2020)

    Abstract

    Pseudotyped viruses are useful virological tools because of their safety and versatility. On the basis of a vesicular stomatitis virus (VSV) pseudotyped virus production system, we developed a pseudotyped virus-based neutralization assay against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in biosafety level 2 facilities. Compared with the binding antibody test, the neutralization assay could discriminate the protective agents from the antibody family. This protocol includes production and titration of the SARS-CoV-2 S pseudotyped virus and the neutralization assay based on it. Various types of samples targeting virus attachment and entry could be evaluated for their potency, including serum samples derived from animals and humans, monoclonal antibodies and fusion inhibitors (peptides or small molecules). If the pseudotyped virus stock has been prepared in advance, it will take 2 days to get the potency data for the candidate samples. Experience in handling cells is needed before implementing this protocol.

  • 原文来源：https://www.nature.com/articles/s41596-020-0394-5
96浏览量
原文链接
相关报告

  • 《Nature，3月25日，Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-03-29
    • Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice Raoul De Gasparo, Mattia Pedotti, […]Luca Varani Nature (2021) Abstract Neutralizing antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) are among the most promising approaches against coronavirus disease 2019 (COVID-19)1,2. We developed a bispecific, IgG1-like molecule (CoV-X2) based on two antibodies derived from COVID-19 convalescent donors, C121 and C1353. CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, prevents detectable S binding to Angiotensin-Converting Enzyme 2 (ACE2), the virus cellular receptor. Furthermore, CoV-X2 neutralizes SARS-CoV-2 and its variants of concern, as well as the escape mutants generated by the parental monoclonals. In a novel animal model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, combining into a single molecule the advantages of antibody cocktails.
    207浏览量
    原文链接

  • 《Nature，10月16日，Rabies virus-based COVID-19 vaccine CORAVAX? induces high levels of neutralizing antibodies against SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-11-16
    • Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2 Drishya Kurup, Christoph Wirblich, Holly Ramage & Matthias J. Schnell npj Vaccines volume 5, Article number: 98 (2020) Abstract The recently emerged coronavirus SARS-CoV-2, the causative agent of COVID-19, is rapidly spreading in the world. The exponentially expanding threat of SARS-CoV-2 to global health highlights the urgent need for a vaccine. Herein we show the rapid development of a novel, highly efficient, and safe COVID-19 vaccine using a rabies virus-based vector that has proven to be an efficient vaccine against several emerging infectious diseases. This study reports that both a live and an inactivated rabies virus containing the SARS-CoV-2 spike S1 protein induces potent virus-neutralizing antibodies at much higher levels than seen in the sera of convalescent patients. In summary, the results provided here warrant further development of this safe and established vaccine platform against COVID-19.
    133浏览量
    原文链接